NCT02886065 2026-03-13
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
Phase 1 Active not recruiting
Clinical Trials
13 trialsNCT05767359 2026-03-12
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04850846 2026-02-09
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04370483 2026-01-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Phase EARLY_PHASE1 Active not recruiting
NCT01177527 2025-11-26
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
Active not recruiting
NCT04920084 2025-09-09
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05831358 2025-08-17
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
Phase NA Active not recruiting
NCT03236428 2025-03-05
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04023747 2025-02-03
OxPLoreD
University of Oxford
Active not recruiting
NCT03289299 2023-12-12
ASCENT
International Myeloma Foundation
Phase 2 Active not recruiting
NCT03673826 2023-11-01
HO147SMM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT02415413 2022-09-10
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
PETHEMA Foundation
Phase 2 Active not recruiting